Nearly Three In Four Infants Were Immunized Against RSV During 2023-24 Season, Study Finds

Healio (6/25, Kellner, DiBerardino) reports a study examined data from 10 US health systems and found that “nearly three-quarters of infants were immunized against respiratory syncytial virus through maternal vaccination or nirsevimab during the first season those products were available.” In the study, researchers found that out of 36,949 dyads of babies whose mothers were eligible for the maternal vaccine from September 2023 through March 2024, “31.9% received the maternal RSV vaccine and 42.5% received nirsevimab.” They found that 72% of infants who “were exposed to the maternal vaccine less than 14 days before birth” also “received nirsevimab after birth, which aligns with recommendations from the CDC’s Advisory Committee on Immunization Practices.” Overall, researchers “estimated that 71.7% of infants born during the 2023-2024 season were immunized against RSV.” The study was published in Pediatrics.